Citadel Advisors
XTLB

Citadel Advisors’s XTL Biopharmaceuticals XTLB Stock Holding History

Citadel Advisors’s Portfolio XTLB Stock Details XTLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,967
Closed -$44K – 14404
2025
Q4 		$44K Buy
+18,967
New +$76.8K ﹤0.01% 12092
2025
Q2 		– Sell
-6,303
Closed -$31.3K – 15423
2025
Q1 		$31.3K Buy
+6,303
New +$38.6K ﹤0.01% 12782
2024
Q3 		– Sell
-3,859
Closed -$36.6K – 15396
2024
Q2 		$36.6K Buy
3,859
+451
+13% +$4.62K ﹤0.01% 12075
2024
Q1 		$38.3K Buy
+3,408
New +$15.8K ﹤0.01% 12442
2021
Q4 		– Sell
-3,200
Closed -$56K – 14900
2021
Q3 		$56K Buy
+3,200
New +$51.6K ﹤0.01% 13311
2019
Q4 		– Sell
-4,564
Closed -$26K – 9865
2019
Q3 		$26K Buy
+4,564
New +$33.9K ﹤0.01% 8881
2018
Q3 		– Sell
-4,328
Closed -$33K – 9768
2018
Q2 		$33K Buy
+4,328
New +$32.5K ﹤0.01% 8543
2017
Q1 		– Sell
-4,159
Closed -$50K – 8130
2016
Q4 		$50K Buy
4,159
+629
+18% +$9.54K ﹤0.01% 6869
2016
Q3 		$67K Buy
+3,530
New +$76.5K ﹤0.01% 6780
2016
Q2 		– Sell
-793
Closed -$17K – 7500
2016
Q1 		$17K Buy
+793
New +$20.4K ﹤0.01% 6520

Other funds holding XTLB

NI
Noked Israel Ramat Hasharon, Israel $970M AUM 74.09% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $309M AUM
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors's XTLB Position: Q1 2026 in Review

Citadel Advisors sold out of XTL Biopharmaceuticals (XTLB) in Q1 2026, closing a stake of 18,967 shares — an estimated $44K sold.

Citadel Advisors first reported a position in XTLB in Q1 2016 and held it in 10 quarters. The position peaked at $67K in Q3 2016. 6 funds tracked by Wall St. Rank hold XTLB as of Q1 2026.

  • Citadel Advisors reported no remaining XTL Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 18,967 XTL Biopharmaceuticals shares in Q1 2026, an estimated $44K.
  • Citadel Advisors first reported a position in XTL Biopharmaceuticals in Q1 2016 and held it in 10 quarters.
  • Citadel Advisors's XTL Biopharmaceuticals position peaked at $67K in Q3 2016.
  • 6 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.